PCR110 Improving Patients’ Well-Being and Psoriasis-Related Work Productivity With Tildrakizumab: 52-Week Interim Results From the Phase IV Real-World Positive Study in Patients With Moderate-to-Severe Plaque Psoriasis | Publicación